{"id":"W4396217735","doi":"10.1001/jamaneurol.2024.0991","title":"Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease","year":2024,"lang":"en","type":"letter","venue":"JAMA Neurology","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; McGill University","funders":"National Institute of Mental Health; National Institute on Aging; Novo Nordisk Canada; Genentech; National Institutes of Health; Deutsches Zentrum für Neurodegenerative Erkrankungen; Novo Nordisk; Eisai; BrightFocus Foundation; Eli Lilly and Company; Alzheimer's Research Trust; Good Ventures Foundation; Centene Corporation; Seagen; Avid Radiopharmaceuticals; Atara Biotherapeutics; GHR Foundation; Canadian Institutes of Health Research; Foundation for Barnes-Jewish Hospital; Prothena; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Cure Alzheimer's Fund; Washington University in St. Louis; F. Hoffmann-La Roche; Bayer Vital; Coins for Alzheimer's Research Trust; Bristol-Myers Squibb; Eisai Canada; Korea Health Industry Development Institute; Biogen; TauRx Pharmaceuticals; Alzheimer's Association; Sanofi; Foundation for the National Institutes of Health","keywords":"Biomarker; Neurogranin; Medicine; Internal medicine; Oncology; Placebo; Pharmacology; Alzheimer's disease; Neurodegeneration; Cerebrospinal fluid; Gastroenterology; Pathology; Chemistry; Disease; Biochemistry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001213645,0.0006150189,0.0008084895,0.0002587854,0.0001407051,0.0004311329,0.0002532612,0.0004926585,0.001532484],"category_scores_gemma":[0.001222622,0.0001766227,0.0007406726,0.0001723205,0.0003601642,0.0004554628,0.0002133411,0.0004925672,0.0001510841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003292067,"about_ca_system_score_gemma":0.0002870412,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002729956,"about_ca_topic_score_gemma":0.00072267,"domain_scores_codex":[0.9995015,0.0002712729,0.00004461141,0.00008861671,0.00004558062,0.00004846857],"domain_scores_gemma":[0.9994391,0.0001630208,0.000217274,0.00003792328,0.00004220372,0.0001004592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7177511,0.006968115,0.07865869,0.00144942,0.002478223,0.0003150827,0.0001420808,0.0007202706,0.07530207,0.0001372918,0.0007491779,0.1153285],"study_design_scores_gemma":[0.07502639,0.336692,0.5436516,0.0002558847,0.005120394,0.0009765083,0.0002125939,0.00170286,0.032552,0.0006516751,0.003090304,0.00006782986],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962683,0.002873407,0.00007448444,0.00006435986,0.00002232682,0.00005587987,0.000166825,0.000007635583,0.000466734],"genre_scores_gemma":[0.998531,0.0005759018,0.0002545916,0.00009440359,0.00002522712,0.00005992919,0.0001927066,0.000001738568,0.0002645043],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001532484,"threshold_uncertainty_score":0.006418407,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02827269638996045,"score_gpt":0.3081638165106408,"score_spread":0.2798911201206803,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}